Neuvivo Expands Board for Upcoming NDA Review with Robert Baffi
29 Oct 2024 //
BUSINESSWIRE
Breakthroughs In Preserving ALS Lung Function Unveiled In Studies
16 Oct 2024 //
BUSINESSWIRE
Neuvivo Seeks FDA Approval for Its Breakthrough ALS Treatment NP001
07 Oct 2024 //
BUSINESSWIRE
Neuvivo Appoints Mark Henderson As VP Of Manufacturing
22 Aug 2024 //
PR NEWSWIRE
Neuvivo Appoints Matthew W. Davis As New Chief Medical Officer
21 Aug 2024 //
PR NEWSWIRE
Neuvivo Names Dr. James Kovach as Chief Medical Affairs Officer
17 Jan 2024 //
PR NEWSWIRE
Neuvivo Raises $11M in Venture Financing to Develop Treatment for ALS
15 Jun 2023 //
PR NEWSWIRE
Neuvivo`s NP001 for Treatment of ALS Slows Disease Progression
01 Dec 2022 //
PRNEWSWIRE